Maze Therapeutics Cash Flow Statement
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics free cash flow
In fiscal 2025, Maze Therapeutics generated -$111.9 million of operating cash flow and spent $794,000 on capital expenditures. That left free cash flow of -$112.7 million. Free cash flow was down 250.7% from the prior year's $74.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Net Income | -131.12M | 52.23M |
| Net Income growth (YoY) | -351.04% | — |
| Depreciation & Amortization | 2.40M | 3.30M |
| Stock-Based Compensation | 16.40M | 9.65M |
| Change in Working Capital | 3.99M | 1.30M |
| Operating Cash Flow | -111.94M | 75.95M |
| Capital Expenditures | -794.00K | -1.15M |
| Investing Cash Flow | -170.96M | -1.15M |
| Financing Cash Flow | 275.34M | 92.85M |
| Net Change in Cash | -7.57M | 167.65M |
| Free Cash Flow | -112.73M | 74.81M |
This table shows 2 annual periods of Maze Therapeutics's cash flow statement, from FY 2025 back to FY 2024, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a cash flow statement?